SCHEMBL6795494

SCHEMBL6795494

CC(=O)Nc1ccc(-c2cccc(Nc3ncccc3N)c2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 2/20 0.54
ABCG2 Q9UNQ0 4/20 0.49
MAP4K4 O95819 1/20 0.49
CYP17A1 P05093 1/20 0.49
CYP11B1 P15538 1/20 0.49
CYP11B2 P19099 1/20 0.49
FYN P06241 1/20 0.47
USP7 Q93009 1/20 0.47
HDAC1 Q13547 3/20 0.47
CHEK2 O96017 1/20 0.46
ALDH1A1 P00352 2/20 0.46
MAPT P10636 2/20 0.46
HDAC3 O15379 2/20 0.46
HDAC2 Q92769 2/20 0.46
KDM4E B2RXH2 1/20 0.46
MEN1 O00255 1/20 0.46
MAPK1 P28482 1/20 0.46
KMT2A Q03164 1/20 0.46
PIP4K2A P48426 1/20 0.46
PIP4K2B P78356 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6800292 0.94 ABCG2 (0.55) SYKABCG2MAP4K4CYP17A1CYP11B1
SCHEMBL6793593 0.87 ABCG2 (0.57) ABCG2ALDH1A1MAPTKDM4EMEN1
SCHEMBL6792631 0.82 PDE5A (0.47) SYKABCG2CYP11B1CYP11B2ALDH1A1
SCHEMBL6790858 0.82 MEN1 (0.53) SYKABCG2CYP17A1CYP11B1CYP11B2
SCHEMBL30269605 0.82 CA12 (0.49) SYKABCG2MAPTKDM4EMEN1
SCHEMBL6795594 0.82 CA12 (0.49) SYKABCG2MAPTKDM4EMEN1
SCHEMBL6797836 0.81 CA12 (0.48) SYKABCG2MAPTKDM4EMEN1
SCHEMBL6798713 0.79 CA12 (0.47) SYKABCG2CYP17A1CYP11B1CYP11B2
SCHEMBL6792401 0.79 ROCK1 (0.53) SYKABCG2ALDH1A1MAPTKDM4E
SCHEMBL8577619 0.77 SMN1; SMN2 (0.70) CYP17A1CYP11B1CYP11B2ALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6727245-B2 4-(HETERO)ARYL-3-OXO-3,4-DIHYDROPYRIDO(2,3-B)PYRAZINE DERIVATIVES; PROPHYLACTIC OR THERAPEUTIC TREATMENT OF PHOSPHODIESTERASE IV AND TUMOR NECROSIS FACTOR MEDIATED DISEASES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-04-27 US disclosed
EP-0770079-B1 HETEROBICYCLIC DERIVATIVES FUJISAWA PHARMACEUTICAL CO (JP) 2003-02-12 EP disclosed
US-20020107251-A1 Heterobicyclic derivatives FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-08-08 US disclosed
US-6426345-B1 PHOSPHODIESTERASE INHIBITORS; ANTIINFLAMMATORY AGENTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-07-30 US disclosed
EP-0920867-A1 Pyrido[2,3-a]pyrazine derivatives as PDE-IV and TNF inhibitors FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1999-06-09 EP disclosed
EP-0770079-A1 HETEROBICYCLIC DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1997-05-02 EP disclosed
WO-1996001825-A1 HETEROBICYCLIC DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1996-01-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107251-A1 Heterobicyclic derivatives ARSA, ARRB1, SULT2A1 SYK 4373/4885ABCG2 44/4885MAP4K4 4470/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.